Objectives To examine cardiac biomarkers over time in youth-onset type 2 diabetes, and relate serum concentrations to cardiovascular disease risk factors, and left ventricular structure and function.
Conclusions Elevated serum concentrations of cardiac biomarkers were common in youth with type 2 diabetes, but their clinical significance is unclear and will require further long-term study. (J Pediatr 2018; 192:86-92 ).
Trial registration ClinicalTrials.gov NCT00081328.
Y outh with type 2 diabetes (T2D) are at high lifetime risk for cardiovascular disease (CVD). 1 The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study, a randomized clinical trial of 3 glycemic control treatments in newly diagnosed youth with T2D, reported that CVD risk worsened over 2-6 years. [2] [3] [4] Adverse profiles of inflammatory markers including high-sensitivity C-reactive protein, interleukin-6, plasminogen activator inhibitor-1, and homocysteine were described, and these did not improve. 4 Cross-sectional echocardiographic studies of adolescents with T2D demonstrate high concentrations of left ventricular (LV) mass, high measures of relative wall thickness to cavity dimensions, high left atrial (LA) size, and possible diastolic dysfunction. [5] [6] [7] In adults with T2D, measurement of cardiovascular and inflammatory biomarkers adds to CVD risk stratification. 8 Cardiac biomarkers, including brain natriuretic peptide (BNP), and high-sensitivity troponin (troponin), have been associated with adverse cardiac structure or function changes in adults with T2D. 10 Tumor necrosis factor alpha (TNF-a), an inflammatory marker, is also associated with the presence of T2D. A study of Asian Indians with youth-onset T2D showed this relationship in obese and nonobese patients. Laboratory studies have implicated TNF in regulation of myocardial cell function. 11 Two large cohort studies of T2D suggest TNF receptor 1 (R1) and TNF receptor 2 (R2) predict future kidney disease, CVD, and total mortality. [12] [13] [14] There are limited longitudinal data on cardiac biomarkers in children and adolescents, including at-risk populations, such as those with youth-onset T2D. The purpose of this report is to determine the (1) natural history of BNP, troponin, TNFa, TNF-R1, and TNF-R2 over time in youth with T2D, (2) relationship of these cardiac biomarkers to CVD risk factors and hemoglobin A1c (HbA1c), and (3) relationships of these biomarkers to echocardiographic measures of LV structure and function. The finding of worsening biomarker profiles over time or a relationship to cardiac structure and function would suggest subclinical diabetic cardiomyopathy in this young population.
Methods
The TODAY study was a multicenter, randomized clinical trial (ClinicalTrials.gov: NCT00081328) of 3 treatments for T2D in youth: metformin alone, metformin and intensive lifestyle, and metformin and rosiglitazone. 2 Eligibility included age 10-17 years, T2D duration <2 years, body mass index (BMI) ≥85th percentile, negative pancreatic autoantibodies, fasting C-peptide >0.6 ng/mL, and an adult caregiver willing to support study participation. Subjects were excluded for refractory hypertension or creatinine clearance <70 mL/min. The primary objective was to compare treatment arms on time with treatment failure (HbA1c ≥8% [≥64 mmol/mol] for 6 months or sustained metabolic decompensation requiring insulin). Onehalf of the cohort reached the primary endpoint and results demonstrated that adding rosiglitazone to metformin was associated with more durable glycemic control. 2 The protocol was approved by an External Evaluation Committee convened by the National Institute of Diabetes and Digestive and Kidney Disease and by the Institutional Review Boards for the Protection of Human Subjects of each participating institution. All participants provided informed consent and minor children confirmed assent according to local guidelines. A Data and Safety Monitoring Board convened by the National Institute of Diabetes and Digestive and Kidney Disease reviewed progress, safety, and interim analyses throughout the study.
Assessments were obtained at months 0, 12, 24, 36, 48, and 60, as previously described. 5 These included measurements of height, weight, blood pressure (BP) and laboratory testing. Hypertension was defined as BP ≥130/80 mm Hg or ≥95th percentile for age, sex, and height 2, 3 and was treated with an angiotensin-converting enzyme inhibitor. Additional medications were added as needed.
HbA1c and cardiac biomarkers measurements were performed at the Northwest Lipid Research Laboratory, University of Washington, Seattle, Washington. Blood samples were collected yearly in EDTA tubes, centrifuged, frozen immediately upon sample processing and stored in 24/7 monitored -80°C freezers. Analyses were performed immediately after samples were thawed. Serum BNP concentrations were measured by ELISA (Raybio Tech Inc, Norcross, Georgia), with intra-assay and interassay coefficient of variations of 10% and 12%, respectively. Troponin, TNF-a, TNF-R1, and TNF-R2 assays were performed using a Multiplex protein arrays system using magnetic beads (R&D systems, Minneapolis, Minneapolis, and EMD Millipore Inc, Gibbstown, NJ). Intraassay and interassay CVs were 6.5% and 11% for troponin respectively, 7.2% and 12.5% for TNF-a, 3.0% and 3.3% for TNF-R1, and 2.3% and 2.8% for TNF-R2.
Two-dimensional guided echocardiograms were performed on participants during the last year of the study according to American Society of Echocardiography standards by certified technicians as previously described. 5, 15 Images were transferred to a central reading laboratory where MMode measurements of LV wall thicknesses in diastole, LV dimensions in systole and diastole, and dimension were performed; tissue Doppler imaging was used to measure diastolic function. The tricuspid annular plane systolic excursion was measured to assess right ventricular function. Study quality was graded and only studies of fair or better quality were included. Quality control procedures showed a coefficient of variation for repeat measurement of all parameters of <10%.
Statistical Analyses
Statistical analyses of the biomarker data were performed on TODAY participants (n = 521) with at least 2 annual assessments including baseline. TODAY participants completed an average of 4 annual examinations (SD, 1; min-max, 2-6). Abnormal risk categories, based on current consensus, were applied to 3 of the 5 cardiac biomarkers (BNP, ≥100 pg/mL 16 ; troponin, ≥0.01 pg/mL 17 ; TNF-a, ≥5.6 pg/mL 18 ). A cutoff of ≥0.04 pg/mL 19 for troponin was also examined. Participants were grouped into 3 categories for BNP, troponin, and TNF-a: (A) always normal (values less than the cutoff at all annual visits), (B) intermittent (at least 1 visit with a value ≥l to the cutoff), and C) always high (values greater than or equal to the cutoff at all annual visits). TNF-R1 and TNF-R2 were normally distributed and analyzed as continuous variables or by tertiles. Generalized linear models were used to assess the relationships between treatment group, raceethnicity, T2D parameters, risk factors, or echocardiography parameters with the cardiac biomarkers concentrations at (a) baseline, (b) end of the study, and (c) grouped into categories (always abnormal, intermittent, always normal). Models evaluating longitudinal data accounted for the multiple observations per participant as appropriate. Analyses included all data available up to as many as 6 annual visit time points (range, 24-60 months). Sensitivity analyses were conducted on those with a minimum of 4 visits (n = 340) to ensure reported results were not biased by those with fewer visits.
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Echocardiography variables not normally distributed were logtransformed. All models were adjusted for time in the study. Models for BNP were further adjusted for sex and antihypertensive medications use. Treatment group and failure to maintain glycemic control were not included as covariates in the final models because no univariate associations were identified with the biomarkers and their adjustment in the models did not impact the relationships between the biomarkers and the CVD risk factors and echocardiography measures. Analyses were performed in SAS (version 9.4 for Windows; SAS Institute, Cary, North Carolina), and considered exploratory and hypothesis generating. P < .05 was used to determine statistical significance.
Results
Participants were 36% male, obese (BMI 35 kg/m 2 at baseline and 37 kg/m 2 at the end of the study), and ethnically diverse: 34% African American, 43% Hispanic, and 20% white ( Table I) . By the end of the study, the median duration of T2D was 4.1 years with about one-half achieving the primary endpoint (failure to maintain glycemic control). Hypertension requiring antihypertensive medications increased from baseline (4.4% vs 27.8%). Average LV mass and LA size were increased ( Table I) . 5 Baseline and end-of-study values for the 5 cardiac biomarkers are presented in the Figure. Elevated serum BNP concentrations (≥100 pg/mL) were found in 17.5% at baseline (Figure, A) . The BNP distribution was positively skewed, with no overall change in the prevalence of abnormal BNP values (ie, ≥100 pg/mL) over the course of the study. Overall, 128 (24.6%) of participants had elevations of BNP; 57 (44.5%) had abnormal values on every assessment and 48 (37.5%) had abnormal values on ≤50% of assessments.
To determine if BNP was associated with treatment group, race-ethnicity, T2D duration, HbA1c, loss of glycemic control, sex, BMI, antihypertensive medication use, BP, or echocardiography parameters, the cohort was divided into 3 groups: always normal (n = 393), always high (n = 57), and intermittent (n = 71). For LV diastolic function, there was a trend toward a higher E (P = .0210) and E/Em ratio (P = .0223) in those with consistently high BNP level (mean [SD], always high 97.5 [20.5] The distribution of troponin was positively skewed, with most values close to zero (Figure, B) . The prevalence of abnormal troponin values (≥0.01 pg/mL) was not statistically different at the end-of-study visit (31.1%) compared with baseline (34.2%; P = NS), with tremendous variability from visit to visit. Only 43.0% of the cohort (n = 224) had a normal value (<0.01 pg/mL) at every annual visit; 19.8% (n = 103) had an abnormal value at 1 visit only, 15.4% (n = 80) at 2 visits, 11.1% (n = 58) at 3 visits, and 10.8% (n = 56) at all visits.
When the cohort was divided into 3 groups-always normal (<0.01 pg/mL; n = 224), always high (n = 56), and intermittent (n = 241)-no relationship was found for any of the parameters or characteristics, except for BMI (Table III TAPSE, tricuspid annular plane systolic excursion. *Mean (SD) or percent are shown; based on a sample of n = 521 TODAY participants with at least 2 annual assessments collected including a baseline visit; mean (SD) duration in the study was 3.4 (1.2) years at the end-of-study visit.
THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 192 related to presence of elevated troponin were found by treatment group, race-ethnicity, diabetes parameters, risk factors, or other echocardiography parameters. When analyses were performed with a 0.04 pg/mL cutoff, similar results were found. The distribution of TNF-a was positively skewed, with elevated serum concentrations (≥5.6 pg/mL) in 18.3% of participants at baseline (Figure, C) . There was no change in the prevalence of abnormal TNF-a values over the course of the study. Values were normal at all visits in 67.6% of participants, with 11.9% having a single elevation, and 8.1% being elevated at all examinations. When divided into 3 groups (always normal, intermittent, and always high), those with at least 1 elevation during the study (n = 127) had higher LV mass index than those always normal (mean [ TNF-R1 and TNF-R2 serum concentrations were normally distributed across the cohort ( Figure, D and E) . Mean values were significantly higher than reported in nondiabetic cohorts. 18 Visit-to-visit correlation for TNF-R1 and TNF-R2 were strong (correlation coefficient, 0.70-0.86). Longitudinal repeated measures analyses indicated no change over time in receptor concentrations. For both TNF-R1 and TNF-R2, there was a graded relationship with participants in the highest tertiles having greater BMI and BMI-associated risk factors: systolic BP, LV mass, LV relative wall thickness, and LA diameter ( Table V and Table VI ; available at www.jpeds.com). There was also a relationship to LV Em and E/Em ratio tissue Doppler imaging ( Table V) . Because TNF-R1 and TNF-R2 were strongly related to BMI, relevant comparisons were adjusted for BMI. All significance disappeared after adjustment for BMI, except for the relationship between end-of-study TNF-R1 and TNF-R2 with LV Em (P = .01 and P = .007, respectively). No differences related to treatment group, race-ethnicity, diabetes duration, risk factors, or echocardiographic parameters were found. Similar results were obtained when analyses were repeated based on TNF-R1 and TNF-R2 tertiles during the study (data not shown).
Discussion
In this analysis of longitudinal trends in cardiac biomarkers in youth with T2D, there are novel and clinically relevant observations. Importantly, no adverse trends in biomarker concentrations during 2-6 years of treatment were observed, suggesting an absence of subclinical changes in cardiac function in the early course of adolescent T2D. For biomarkers that are not normally distributed (BNP, troponin, and TNF-a), we observed high visit-to-visit variability, especially for troponin, with a relatively high frequency of values outside the Figure.
Baseline and end-of-study distributions of measures of A, BNP, B, troponin, C, TNF-a, D, TNF-R1, and E, TNF-R2. A reference line (dashed line) and the percent of participants above a pre-specified abnormal cutoff is illustrated in the graph for BNP (cutoff, 100 pg/mL), troponin (cutoff, 0.01 ng/mL), and TNF-a (5.6 pg/mL). TNF-R1 and TNF-R2 are normally distributed and therefore the mean (SD) is given; the reference line (dashed line) represents the upper normal range reported in the literature (TNF-R1: 821 pg/mL, and TNF-R2: 2622 pg/mL).
normal range at any individual visit. In a few individuals, BNP and TNF-a remained consistently high. These data suggest that, although abnormalities in these biomarkers are prevalent in adolescents with T2D, they should not be considered pathologic without repeat measurement and clinical correlation. TNF-R1 and TNF-R2 values were associated with systolic BP and several cardiac structure and function parameters, but these relationships seemed to be driven by BMI. TNF-a and BNP concentrations were not related to BMI, although there was a trend for those with variable troponin concentrations to have a higher BMI. Nonetheless, the frequency of values outside reported ranges, particularly for BNP, troponin, and TNF-a receptor, remains concerning. In older adults, cardiovascular and inflammatory biomarkers are related to CVD outcomes over a relatively short follow-up interval. 8 Although adolescents with T2D have a significant lifetime risk for CVD, they may have a lower short-term risk for adverse outcomes than adults. These biomarkers also have been associated with other adverse outcomes. For example, higher TNF-a concentrations have been associated with BP disorders of pregnancy and lower newborn birth weight. [20] [21] [22] [23] [24] Long-term follow-up of this cohort to determine the clinical implications for these findings is necessary.
There were few significant associations between the biomarkers, CVD risk factors, and echocardiographic parameters. There were no relationships to treatment group, race-ethnicity, diabetes duration, or risk factors (other than BMI for TNF-R1 and TNF-R2). TNF-a elevation was related to worse glycemic control, but the other markers did not show this association. With regard to echocardiographic parameters, persistently elevated troponin was related to higher LV relative wall thickness and lower tricuspid annular plane systolic excursion. TNF-a was related to higher LV mass index. However, given the large number of comparisons and .05 < P < .01 among the relationships, these findings should be considered hypothesis generating rather than confirmed positive associations. BNP was unrelated to any echocardiographic parameters.
Collectively, these data do not support a role for the routine measurement of these biomarkers during the care of adolescents with T2D. They may actually be misleading, for example, in the evaluation of chest pain. Most studies of biomarkers in children and adolescents report single measures and only cross-sectional correlations. A strength of this analysis is that these longitudinal measurements combined with other TODAY study findings allowed for evaluation of chronic exposure and relationships to baseline parameters. *Mean during the study. †All models adjusted for time in study (ie, similar to duration of diabetes). All echocardiography LV and Doppler diastology parameters are log transformed before testing due to skewed distributions. Pairwise comparisons are given for the significant associations found (P < .05). All significant relationships disappear after adjustment for BMI in the models, except for LV Em (adjusted P = .01).
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BNP is most commonly measured for heart failure assessment. 25, 26 In this study, BNP elevations were not associated with measures of cardiac function. In healthy adults, BNP is not a marker for future heart failure or adverse events. 27 In adults with T2D and/or hypertension, BNP predicts future events in older, but not younger, patients. 26, 28, 29 There are many studies suggesting a link between BNP concentrations and future diabetes vascular complications; however, there are limited pediatric data. 26 Because atrial and ventricular stretch may vary depending on diabetes control, blood volume, and other factors impacting cardiac chamber size, the variation of individual values may occur and explain the results presented. Long-term follow-up of adolescents with T2D will be needed to determine the prognostic value of BNP measurement.
Measurement of troponin is typically used to diagnose myocardial infarction in emergency or urgent care settings. 17, 30 Elevated troponin has been associated with myocardial injury, including myopericarditis. 31 The value of troponin as a longterm predictor of myocardial outcomes is uncertain. There is no prior information on troponin in youth with T2D. The finding that more than one-half the participants in the TODAY study had an elevated value at least once suggests that subclinical and mild myocardial injury occurs in T2D. Elevated values in asymptomatic individuals should not be considered pathologic. Their value in symptomatic individuals in the TODAY age range is unknown, but our data suggest that there might be high false-positive rates.
TNF-a is a proinflammatory adipocytokine. 32 Elevated concentrations may increase insulin resistance by downregulating genes required for insulin action and directly affecting insulin transduction to impair glucose metabolism and stimulate lipolysis. [33] [34] [35] There is evidence that increased TNF-a concentrations may contribute directly to myocardial insulin resistance. 36 In this study, TNF-a concentrations did not substantially change over 2-6 years of follow-up, suggesting that the inflammatory status as monitored by this biomarker was stable. TNF-a concentrations are not modified by bariatric surgery. 37 This is in contrast with findings with regard to highsensitivity C-reactive protein, interleukin-6, and plasminogen activator inhibitor-1 levels, which increased during TODAY follow-up. 4 By the end of the study, TNF-a concentrations showed an association with LV mass, BP, and HbA1c.
TNF-R1 and TNF-R2 concentrations add to the assessment of TNF-a systemic activation, particularly when TNF-a is degraded rapidly. These biomarkers were initially associated with progression of renal impairment in T2D, but, more recently, have been associated with CVD and all-cause mortality. 12, 13 In this study, these variables were strongly associated with several CVD risk factors and echocardiographic traits; however, after adjustment for BMI, these relationships were completely attenuated. In the absence of an obese nondiabetic control group, we cannot be certain if this adverse distribution in the TODAY cohort is due to obesity alone or is related to diabetes.
The collection of biomarker data was not a primary aim of the TODAY study. A change in laboratory values related to prolonged storage or stability of specimens could have occurred.
All specimens were analyzed simultaneously, without freezethaw cycles, minimizing assay variation risk. End-of-study laboratory data could have been collected up to 3 months from the time of the echocardiogram. There were a variable number of measurements of each biomarker (range, 2-6) across the cohort creating missing data, but sensitivity analyses did not suggest that this created a bias. There was no lean or obese nondiabetic control group and markers of adequate day-to-day hydration were not available. Epicardial fat as an independent measure of influence of fat on outcomes was not measured.
The role of cardiac biomarkers in the assessment and management of youth with T2D is uncertain. Long-term followup of this cohort is required to understand the prognostic value of these markers, particularly BNP, in identifying those at risk for future ventricular dysfunction, heart failure, or other CVD complications. Unlike conventional risk factors, such as lipids and BP, these cardiac biomarker concentrations did not worsen during follow-up of the TODAY cohort. 3, 4 Owing to the high variability of troponin, BNP, and TNF-a measurements, providers should exert caution in interpretation of isolated values, particularly in the absence of clinical symptoms or a CVD diagnosis. ■ ACE, angiotensin-converting enzyme. *Mean during the study. †All models adjusted for time in study (ie, similar to duration of diabetes), antihypertensive medications use, and sex. All echocardiography LV and Doppler diastology parameters are log transformed before testing due to skewed distributions. Pairwise comparisons are given for the significant associations found (P < .05). †All models adjusted for time in study (ie , similar to duration of diabetes). All echocardiography LV and Doppler diastology parameters are log transformed before testing due to skewed distributions. Pairwise comparisons are given for the significant associations found (P < .05). †All models adjusted for time in study (ie, similar to duration of diabetes). All echocardiography LV and Doppler diastology parameters are log transformed before testing due to skewed distributions. Pairwise comparisons are given for the significant associations found (P < .05). *Mean during the study. †All models adjusted for time in study (ie, similar to duration of diabetes). All echocardiography LV and Doppler diastology parameters are log transformed before testing due to skewed distributions. Pairwise comparisons are given for the significant associations found (P < .05). All significant relationships disappear after adjustment for BMI in the model, except for LV Em (adjusted P = .0069).
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